HA-966

HA-966 (3-amino-1-hydroxypyrrolid-2-one) is a drug that acts as an antagonist for the NMDA receptor. It is less well known than other NMDA antagonists such as ketamine and phencyclidine, but has been researched for potential medical applications.

Pharmacology

HA-966 has been found to act as an antagonist at the NMDA receptor, which is a type of ionotropic glutamate receptor. It has been shown to have neuroprotective effects in animal models of brain injury and neurodegenerative diseases. In addition to its NMDA antagonist properties, HA-966 has also been found to act as a GABA agonist, which may contribute to its neuroprotective effects.

Medical Applications

Research into the potential medical applications of HA-966 has focused on its neuroprotective effects. It has been suggested that the drug could be used to treat conditions such as stroke, traumatic brain injury, and neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease. However, further research is needed to fully understand the potential benefits and risks of HA-966 in these contexts.

Side Effects

As with other NMDA antagonists, the use of HA-966 can potentially lead to a range of side effects. These can include hallucinations, dizziness, and nausea. In addition, long-term use of the drug can potentially lead to tolerance and dependence. Further research is needed to fully understand the side effect profile of HA-966.

See Also

• NMDA receptor antagonist
• Neuroprotection
• Neurodegenerative diseases

HA-966 Resources
Latest articles Most recent articles Ongoing trials	Wikipedia